Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zevalin + busulfan + cyclophosphamide + etoposide
- Development stage
- Unknown
- Lead developer
- Asan Medical Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zevalin-BuCyE is an intensified conditioning regimen developed for patients with B-cell non-Hodgkin lymphoma (NHL) undergoing autologous stem cell transplantation (ASCT). It combines radioimmunotherapy using 90Y-ibritumomab tiuxetan (Zevalin) with a high-dose chemotherapy backbone of busulfan, cyclophosphamide, and etoposide (BuCyE). Zevalin targets the CD20 antigen on B-cells to deliver targeted beta radiation, while the BuCyE components provide broad-spectrum cytoreduction through DNA alkylation and topoisomerase II inhibition. This regimen, often preceded by rituximab to optimize Zevalin distribution, is primarily investigated by Asan Medical Center to improve outcomes in relapsed, refractory, or high-risk NHL patients.
- Brand names
- ZevalinRituxanBusulfexCytoxanToposar
- Other names
- 90Y-ibritumomab tiuxetan + BuCyEZevalin-BuCyE conditioning regimenZevalin with BuCyE Conditioning and ASCT for B-cell NHL
02
Targets
Beyond the preview
Go deeper on Zevalin + busulfan + cyclophosphamide + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zevalin + busulfan + cyclophosphamide + etoposide.